Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Market Closed 06-12 16:00:00 EDT

6.48

+0.05

+0.78%

盘后6.48

+0.000.00%

19:59 EDT

High6.64	Low6.39	Vol460.22K
Open6.43	D1 Closing6.43	Amplitude3.83%
Mkt Cap400.15M	Tradable Cap374.03M	Total Shares61.75M
T/O3.01M	T/O Rate0.80%	Tradable Shares57.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":6.48,"timestamp":1781294400000,"preClose":6.43,"halted":0,"volume":460221,"hourTrading":{"tag":"盘后","latestPrice":6.48,"preClose":6.48,"latestTime":"19:59 EDT","volume":475,"amount":3071.35,"timestamp":1781308779185,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007776049766718618,"floatShares":57721074,"shares":61751800,"eps":-1.35,"marketStatus":"Market Closed","change":0.05,"latestTime":"06-12 16:00:00 EDT","open":6.43,"high":6.6399,"low":6.3936,"amount":3005645,"amplitude":0.038305,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.35,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":6.43,"preHourTrading":{"tag":"盘前","latestPrice":6.53,"preClose":6.43,"latestTime":"09:27 EDT","volume":1582,"amount":10370.50833,"timestamp":1781270870350,"change":0.1,"changeRate":0.015552,"amplitude":0.046656},"postHourTrading":{"tag":"盘后","latestPrice":6.48,"preClose":6.48,"latestTime":"19:59 EDT","volume":475,"amount":3071.35,"timestamp":1781308779185,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6763940426136229,"impliedVol":1.2555,"impliedVolPercentile":0.7211},"requestUrl":"/m/hq/s/SGMT","defaultTab":"news","newsList":[{"id":"2643213127","title":"Sagimet Biosciences Announces Board Changes and Director Elections","url":"https://stock-news.laohu8.com/highlight/detail?id=2643213127","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643213127?lang=en_us&edition=fundamental","pubTime":"2026-06-13 05:00","pubTimestamp":1781298001,"startTime":"0","endTime":"0","summary":"The latest update is out from Sagimet Biosciences, Inc. Class A ( ($SGMT) ). On June 12, 2026, Sagimet Biosciences Inc. announced that board member...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-announces-board-changes-and-director-elections?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-announces-board-changes-and-director-elections?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643290700","title":"Sagimet Biosciences shareholders elect Class III directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643290700","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643290700?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:07","pubTimestamp":1781294871,"startTime":"0","endTime":"0","summary":"Sagimet held its annual stockholder meeting on June 12, 2026.Stockholders backed the selection of four directors to serve through the 2029 annual meeting.KPMG was ratified as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL7sD5RM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640187347","title":"Sagimet Biosciences Grants New Performance-Based Executive Equity Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2640187347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640187347?lang=en_us&edition=fundamental","pubTime":"2026-06-04 06:07","pubTimestamp":1780524433,"startTime":"0","endTime":"0","summary":"An announcement from Sagimet Biosciences, Inc. Class A ( ($SGMT) ) is now available. On May 28, 2026, Sagimet Biosciences Inc.’s board and compensa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-grants-new-performance-based-executive-equity-awards?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-grants-new-performance-based-executive-equity-awards?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4215","SGMT","EQR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640018488","title":"Sagimet Biosciences grants CEO David Happel 300,000 stock options, 300,000 performance-based RSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2640018488","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640018488?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:36","pubTimestamp":1780518984,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences granted equity awards on May 28, 2026 to CEO David Happel, CFO Thierry Chauche, chief legal and administrative officer Elizabeth Rozek.Happel received 300,000 stock options, 300,000 performance-based restricted stock units; Chauche 50,000 of each; Rozek 100,000 of each.Options carry a $7.27 exercise price, matching the May 28 closing price; vest in equal installments over 48 months.PSUs pay out based on regulatory milestones; one-third vests on achievement determination, remainder over two annual installments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL2YMh1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640618806","title":"UK's Mhra: Resmetirom (Rezdiffra) Authorised to Treat Metabolic Dysfunction-Associated Steatohepatitis (Mash) in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2640618806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640618806?lang=en_us&edition=fundamental","pubTime":"2026-06-03 23:28","pubTimestamp":1780500523,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nFWN42B0B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638692504","title":"Sagimet says Phase 1 trial shows denifanstat-resmetirom combo cuts LDL cholesterol in healthy adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2638692504","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638692504?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:03","pubTimestamp":1779879833,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences announced Phase 1 clinical results on denifanstat combined with resmetirom, presented for the first time at EASL 2026.The study showed the combination was generally well-tolerated in healthy adults, with no safety signals reported over the trial period.Data also indicated rapid improvements in cholesterol measures, supporting a potential cardiovascular benefit alongside the MASH rationale.Preclinical findings will be presented at EASL 2026, pointing to complementary mechanisms that could strengthen anti-fibrotic and metabolic effects versus monotherapy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL25XJg3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4139","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","NDAQ","SG9999014039.USD","SGMT","LU2210150020.SGD","LU2095319765.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4585","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2W23.USD","BK4588","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638049325","title":"Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2638049325","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638049325?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879600,"startTime":"0","endTime":"0","summary":"Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid reduc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301763/0/en/Sagimet-Biosciences-Presents-Two-Posters-at-EASL-2026-on-Denifanstat-Resmetirom-Combination-in-MASH.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638544561","title":"Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2638544561","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638544561?lang=en_us&edition=fundamental","pubTime":"2026-05-27 01:47","pubTimestamp":1779817652,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Sagimet Biosciences, Inc. Class A today and set a price target of $29.00. Accordi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-inc-class-a-sgmt-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-inc-class-a-sgmt-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636859703","title":"Sagimet Biosciences Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2636859703","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636859703?lang=en_us&edition=fundamental","pubTime":"2026-05-19 21:01","pubTimestamp":1779195660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2026 09:01 ET (13:01 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636883409","title":"Sagimet Biosciences price target lowered to $12 from $35 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2636883409","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636883409?lang=en_us&edition=fundamental","pubTime":"2026-05-19 17:40","pubTimestamp":1779183608,"startTime":"0","endTime":"0","summary":"Citizens lowered the firm’s price target on Sagimet Biosciences (SGMT) to $12 from $35 and keeps an Outperform rating on the shares. Sagimet Biosci...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-lowered-to-12-from-35-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-lowered-to-12-from-35-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635229729","title":"Sagimet Biosciences files Form 3 for Chief Medical Officer Andreas Grauer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635229729","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635229729?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:14","pubTimestamp":1778793296,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences filed an initial Form 3 for Chief Medical Officer Andreas Grauer, dated April 20, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLbBHDd6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635974920","title":"Sagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2635974920","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635974920?lang=en_us&edition=fundamental","pubTime":"2026-05-14 23:37","pubTimestamp":1778773038,"startTime":"0","endTime":"0","summary":"In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Sagimet Biosciences, Inc. Class A, with a price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-inc-class-a-sgmt-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-inc-class-a-sgmt-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635376338","title":"Sagimet Biosciences price target lowered to $28 from $37 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2635376338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635376338?lang=en_us&edition=fundamental","pubTime":"2026-05-14 09:35","pubTimestamp":1778722551,"startTime":"0","endTime":"0","summary":"Clear Street lowered the firm’s price target on Sagimet Biosciences (SGMT) to $28 from $37 and keeps a Buy rating on the shares. The firm is adjust...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-lowered-to-28-from-37-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-lowered-to-28-from-37-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635732512","title":"Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2635732512","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635732512?lang=en_us&edition=fundamental","pubTime":"2026-05-14 01:45","pubTimestamp":1778694318,"startTime":"0","endTime":"0","summary":"Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Sagimet Biosciences, Inc. Class A. The associated price target remains the same wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sagimet-maintained-at-buy-as-strong-cash-runway-and-advancing-acne-franchise-support-unchanged-28-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sagimet-maintained-at-buy-as-strong-cash-runway-and-advancing-acne-franchise-support-unchanged-28-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635548780","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2635548780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635548780?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:20","pubTimestamp":1778678438,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Electromed (ELMD), Sagimet Biosciences, Inc. Class A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-169?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-169?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4581","BK4137","BLSX","LABU","BK4585","LU0128526141.USD","BK4082","BK4112","ELMD","BLSG","BK4139","LU0029874061.USD","SGMT","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786609","title":"Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786609","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786609?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670000,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., May  13, 2026  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293849/0/en/Sagimet-Biosciences-to-Participate-in-the-H-C-Wainwright-4th-Annual-BioConnect-Investor-Conference-at-NASDAQ.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIW.SI","JEPQ","SGMT","QQQE","QQQ","QDTE","TQQY","GPIQ","QLD","TQQQ","SQQQ","QQQJ","IYW","QYLG","NDX","NQmain","FTEC","BK4139","PSQ",".IXIC","TECS","MNQmain","QQQM","QID","QQQY","QQQA","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634217878","title":"Sagimet Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634217878","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634217878?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:38","pubTimestamp":1778593129,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc reports results for the quarter ended March 31 - Earnings SummarySagimet Biosciences Inc SGMT.OQ reported a quarterly adjusted loss of 33 cents per share for the quarter ended ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P1ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634214361","title":"BRIEF-Sagimet Biosciences Reports First Quarter 2026 Financial Results And Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2634214361","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634214361?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:57","pubTimestamp":1778590633,"startTime":"0","endTime":"0","summary":"BRIEF-Sagimet Biosciences Reports First Quarter 2026 Financial Results And Provides Corporate UpdatesMay 12 (Reuters) - Sagimet Biosciences Inc SGMT.O:SAGIMET BIOSCIENCES REPORTS FIRST QUARTER 2026 FI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1LK5NR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634121688","title":"Sagimet Biosciences Q1 EPS $(0.33) Beats $(0.36) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634121688","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634121688?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:45","pubTimestamp":1778586339,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 41.07 percent increase over losses of $(0.56) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52481291/sagimet-biosciences-q1-eps-0-33-beats-0-36-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634721598","title":"Sagimet Q1 FY26 net loss narrows to $10.7 million; R&D expense drops to $7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634721598","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634721598?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:31","pubTimestamp":1778585467,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences reported a first-quarter net loss of USD 10.7 million, narrowing from USD 18.2 million a year earlier; R&D expense fell to USD 7 million from USD 15.3 million.G&A expense edged up to USD 4.7 million from USD 4.5 million, while cash, cash equivalents and marketable securities stood at USD 104.5 million as of March 31.In April, the company completed an underwritten offering of 29,166,700 shares of Series A common stock at USD 6 per share for USD 175 million in gross proceeds.Phase 3 trial of denifanstat in moderate to severe acne in the U.S. is planned to start in second-half 2026, while first-in-human Phase 1 trial of FASN inhibitor TVB-3567 is ongoing.CEO David Happel said the company is targeting dermatology and expects existing cash and the April financing to fund operations through 2028, including through denifanstat Phase 3 acne data readout.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4HRcd9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0314104364.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4112","IE00BN0W2W23.USD","SGMT","IE00B64PRP62.GBP","BK4588","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":-0.0414},{"period":"1month","weight":-0.1474},{"period":"3month","weight":0.2438},{"period":"6month","weight":0.0401},{"period":"1year","weight":-0.2474},{"period":"ytd","weight":0.0946}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.228208},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.167334},{"month":3,"riseRate":0,"avgChangeRate":-0.107746},{"month":4,"riseRate":0.666667,"avgChangeRate":0.104894},{"month":5,"riseRate":0.666667,"avgChangeRate":0.101166},{"month":6,"riseRate":0.333333,"avgChangeRate":0.225673},{"month":7,"riseRate":0.5,"avgChangeRate":0.061438},{"month":8,"riseRate":0,"avgChangeRate":-0.153918},{"month":9,"riseRate":0,"avgChangeRate":-0.152908},{"month":10,"riseRate":0.666667,"avgChangeRate":0.172366},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.001337},{"month":12,"riseRate":0.333333,"avgChangeRate":0.009885}],"exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}